Sun Pharmaceutical Industries Ltd. closed 10.67% short of its 52-week high of 1,960.20 rupees, which the company achieved on September 30th.

Sun Pharmaceutical Industries Ltd. closed 13.65% short of its 52-week high of 1,960.20 rupees, which the company reached on September 30th.

The rise in the Sun Pharma share price came after a favourable ruling from a US court regarding its planned launch of ...

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

Sun Pharma declined 0.93 per cent to Rs 1,689.35. About10 per cent of the Sun Pharma's US specialty revenues is formulated in ...

According to the USFDA, a Class II recall is issued when the use of or exposure to a violative product may cause temporary or ...

Discover the Sun Pharma Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent stock. Keep track of Sun Pharma with the latest details, including: Last ...

The once-daily pill, currently under investigation, is being studied for adults with type 2 diabetes who are not on any ...

The pharma sector is likely to maintain steady earnings. Most brokerages flag US business recovery as the key swing factor ...

Nifty Pharma index sinks over 2% as Indian drugmakers face tariff heat; Gland, Aurobindo, Biocon, Sun Pharma among top losers ...

Sun Pharma share price has seen a 10% decline in year-to-date (YTD) performance and an 11% drop over the past six months.

Sun Pharma successfully removed an injunction in the US on the launch of its Leqselvi for alopecia areata, a common form of hair loss, that was sought by rival Incyte. The decision in the US Court ...